BRCA1/BRCA2胚系突变携带者与散发性胰腺导管腺癌的预后分析
结果显示突变携带者的中位总生存期和无病生存期均显著劣于野生型,铂类辅助化疗与突变携带者生存改善相关。
要点
- BRCA1/BRCA2胚系突变携带者术后中位OS和DFS均显著差于野生型。
- 铂类辅助化疗与突变携带者生存改善相关,优于其他化疗或无辅助治疗。
- BRCA1/BRCA2突变、切缘阳性及未接受辅助治疗均独立关联更差生存。
核心结论
- 散发性胰腺导管腺癌BRCA1/BRCA2胚系突变携带者接受胰腺切除术后生存差于野生型携带者。
- 铂类辅助化疗与BRCA1/BRCA2突变患者生存显著改善相关,与野生型患者的生存差异不再明显。
研究设计与样本
- 病例对照研究,对2000至2015年切除的散发性胰腺导管腺癌病例行靶向二代测序识别BRCA1/BRCA2胚系突变。
- 从病历中提取人口学、临床病理特征、总生存期和无病生存期进行比较。
主要发现
- BRCA1/BRCA2突变携带者中位总生存期为20.2个月,野生型对照组为27.8个月(p=0.034)。
- BRCA1/BRCA2突变携带者中位无病生存期为8.4个月,野生型对照组为16.7个月(p<0.001)。
- 多因素分析中,BRCA1/BRCA2突变(HR 2.10,p<0.001)、切缘阳性(HR 1.72,p=0.021)和未接受辅助治疗(HR 2.38,p<0.001)均独立关联更差生存。
- 在BRCA1/BRCA2突变组内,接受铂类辅助化疗者(n=10)中位生存31.0个月,其他化疗者(n=8)为17.8个月,无辅助治疗者(n=4)为9.3个月(p<0.001)。
临床怎么用
- 对散发性胰腺导管腺癌切除患者可考虑BRCA1/BRCA2胚系检测以指导辅助化疗选择。
- BRCA1/BRCA2突变携带者优先考虑含铂辅助化疗方案。
- 应重视切缘状态和辅助治疗的实施以改善预后。
局限性
- 铂类化疗亚组分析样本量有限(铂类n=10,其他化疗n=8,无辅助治疗n=4)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The outcomes of sporadic pancreatic ductal adenocarcinoma (PDAC) patients with germline mutations of BRCA1/BRCA2 remains unclear. The prognostic significance of BRCA1/BRCA2 mutations on survival is not well established. STUDY DESIGN: We performed targeted next-generation sequencing (NGS) to identify BRCA1/BRCA2 germline mutations in resected sporadic PDAC cases from 2000 to 2015. Germline BRCA mutation carriers were matched by age and tumor location to those with BRCA1/BRCA2 wild-type genes from our institutional database. Demographics, clinicopathologic features, overall survival (OS), and disease-free survival (DFS) were abstracted from medical records and compared between the 2 cohorts. RESULTS: Twenty-two patients with sporadic cancer and BRCA1 (n = 4) or BRCA2 (n = 18) germline mutations and 105 wild-type patients were identified for this case-control study. The BRCA1/BRCA2 mutations were associated with inferior median OS (20.2 vs 27.8 months, p = 0.034) and DFS (8.4 vs 16.7 months, p < 0.001) when compared with the matched wild-type controls. On multivariable analyses, a BRCA1/BRCA2 mutation (hazard ratio [HR] 2.10, p < 0.001), positive margin status (HR 1.72, p = 0.021), and lack of adjuvant therapy (HR 2.38, p < 0.001), were all independently associated with worse survival. Within the BRCA1/BRCA2 mutated group, having had platinum-based adjuvant chemotherapy (n = 10) was associated with better survival than alternative chemotherapy (n = 8) or no adjuvant therapy (n = 4) (31.0 vs 17.8 vs 9.3 months, respectively, p < 0.001). CONCLUSIONS: Carriers of BRCA1/BRCA2 mutation with sporadic PDAC had a worse survival after pancreatectomy than their BRCA wild-type counterparts. However, platinum-based chemotherapy regimens were associated with markedly improved survival in patients with BRCA1/BRCA2 mutations, with survival differences no longer appreciated with wild-type patients.
引用
- Blair AB, Groot VP, Gemenetzis G, et al. BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma. J Am Coll Surg. 2018. PMID: 29309945. doi:10.1016/j.jamcollsurg.2017.12.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。